A Single-Dose of REGN1908-1909 Reduced Bronchoconstriction in Cat-Allergic Subjects with Mild Asthma for up to 3 months following a controlled cat allergen challenge: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study

Abstract

To evaluate the efficacy of a novel anti-Fel d 1 monoclonal antibody cocktail (REGN1908-1909) in reducing acute bronchoconstriction, defined as early asthmatic response (EAR), in cat-allergic subjects with mild asthma (NCT03838731).